

Table 1.21
U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2017^a
Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			25-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 25 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 25 Years ^d
All Sites	Both Sexes	4,694,674	4,862,424	5,368,372	13,765,686	14,245,784
	Male	2,282,549	2,337,240	2,588,177	6,687,937	6,833,302
	Female	2,412,125	2,525,184	2,780,195	7,077,749	7,412,482
Oral Cavity & Pharynx	Both Sexes	120,057	142,267	147,944	299,078	338,743
	Male	86,288	100,445	103,999	207,083	231,393
	Female	33,769	41,822	43,945	91,995	107,350
Esophagus	Both Sexes	21,960	27,475	27,600	38,441	46,212
	Male	17,415	21,514	21,592	30,048	35,800
	Female	4,545	5,961	6,008	8,393	10,412
Stomach	Both Sexes	44,961	54,096	55,059	93,094	108,211
	Male	25,999	31,415	31,852	52,922	61,445
	Female	18,962	22,681	23,207	40,172	46,766
Colon & Rectum	Both Sexes	393,681	454,445	462,550	1,109,412	1,245,698
	Male	204,702	234,601	239,015	566,874	630,738
	Female	188,979	219,844	223,535	542,538	614,960
Liver & Intrahepatic Bile Duct	Both Sexes	51,270	59,777	60,065	76,638	86,978
	Male	36,730	42,403	42,628	54,559	61,209
	Female	14,540	17,374	17,437	22,079	25,769
Pancreas	Both Sexes	46,309	57,798	57,870	62,314	76,239
	Male	23,182	29,094	29,118	30,794	37,899
	Female	23,127	28,704	28,752	31,520	38,340
Larynx	Both Sexes	28,881	34,622	35,074	75,233	86,330
	Male	23,762	28,382	28,753	61,700	70,504
	Female	5,119	6,240	6,321	13,533	15,826
Lung & Bronchus	Both Sexes	235,457	309,793	322,244	404,633	517,130
	Male	106,454	141,260	146,081	176,811	226,337
	Female	129,003	168,533	176,163	227,822	290,793
Melanoma of the Skin	Both Sexes	304,831	357,073	377,941	947,509	1,059,689
	Male	168,743	201,335	215,605	494,706	560,036
	Female	136,088	155,738	162,336	452,803	499,653
Breast	Female	934,184	1,030,280	1,093,384	2,983,076	3,238,158
Cervix	Female	41,009	43,477	43,662	177,813	187,161
Corpus & Uterus, NOS	Female	207,865	233,888	234,170	605,534	669,026
Ovary ^f	Female	62,580	71,602	71,671	163,605	185,902

^a U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 registries (not including the Alaska Natives Registry) and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 25 years (1992-2016)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2012-2016)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 25-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2017.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 25-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 25-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

^f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Table 1.21 - continued
 U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2017^a
 Using Different Tumor Inclusion Criteria^b

Site	Sex	5-Year Limited Duration			25-year Limited Duration	
		1st Invasive Tumor Ever ^c	1st Per Site in Previous 25 Years ^d	1st Per Site in Previous 5 Years ^e	1st Invasive Tumor Ever ^c	1st Per Site in Previous 25 Years ^d
Prostate	Male	826,957	899,952	900,065	2,947,256	3,135,696
Testis	Male	44,299	45,174	45,735	188,754	192,368
Urinary Bladder	Both Sexes	205,069	259,089	265,383	544,685	650,099
	Male	158,030	199,816	204,940	412,612	491,986
	Female	47,039	59,273	60,443	132,073	158,113
Kidney & Renal Pelvis	Both Sexes	174,099	212,583	216,157	429,086	506,214
	Male	109,433	134,507	136,896	262,352	311,337
	Female	64,666	78,076	79,261	166,734	194,877
Brain & Nervous System	Both Sexes	44,058	47,742	48,179	124,488	130,154
	Male	24,122	26,273	26,512	66,150	69,020
	Female	19,936	21,469	21,667	58,338	61,134
Thyroid	Both Sexes	205,164	231,795	232,442	626,450	686,101
	Male	47,695	56,430	56,607	136,046	153,550
	Female	157,469	175,365	175,835	490,404	532,551
Hodgkin Lymphoma	Both Sexes	35,390	37,895	37,934	146,597	152,671
	Male	19,614	21,106	21,121	77,114	80,200
	Female	15,776	16,789	16,813	69,483	72,471
Non-Hodgkin Lymphoma	Both Sexes	215,280	255,990	261,800	592,703	672,980
	Male	116,184	138,777	141,872	315,105	357,483
	Female	99,096	117,213	119,928	277,598	315,497
Myeloma	Both Sexes	69,911	83,010	83,603	119,296	138,415
	Male	38,921	46,820	47,227	65,614	76,989
	Female	30,990	36,190	36,376	53,682	61,426
Leukemia	Both Sexes	133,638	157,351	157,915	354,813	397,501
	Male	78,659	92,899	93,286	205,064	229,436
	Female	54,979	64,452	64,629	149,749	168,065
Acute Lymphocytic Leukemia	Both Sexes	20,023	20,834	20,842	73,043	74,301
	Male	11,256	11,629	11,629	40,913	41,431
	Female	8,767	9,205	9,213	32,130	32,870
Childhood (Ages 0-19)	Both Sexes	67,519	67,629	68,185	276,483	277,186
	Male	35,671	35,727	36,023	145,459	145,799
	Female	31,848	31,902	32,162	131,024	131,387
Kaposi Sarcoma	Both Sexes	7,443	8,124	8,124	32,836	34,496
	Male	6,804	7,385	7,385	31,200	32,656
	Female	639	739	739	1,636	1,840
Mesothelioma	Both Sexes	3,052	4,124	4,124	4,509	5,804
	Male	2,173	2,902	2,902	2,877	3,706
	Female	879	1,222	1,222	1,632	2,098

^a U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 9 registries and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

^b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion:

^c (c) First invasive tumor ever

^d (d) First invasive tumor for each cancer site diagnosed during the previous 25 years (1992-2016)

^e (e) First invasive tumor for each cancer site diagnosed during the previous 5 years (2012-2016)

For definitions (d) and (e) all sites is treated as a separate cancer "site".

Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2011; Melanoma in 2012.

In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 25-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2017.

In method (d) the 1981 melanoma is counted for the melanoma and all sites 25-year limited duration prevalence. The 2011 breast cancer is counted for the breast 5-year and 25-year limited duration prevalence.

In method (e) the 2011 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2012 melanoma is counted for 5-year limited duration prevalence for melanoma.

Table 1.22
U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2017^a
By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
All Sites									
Males	7,230,811	18,934	46,984	94,237	173,576	326,188	902,270	1,935,304	3,733,319
Females	8,530,128	17,349	39,559	94,470	259,031	636,411	1,465,468	2,240,404	3,777,436
Oral Cavity & Pharynx									
Males	259,578	80	482	1,460	3,675	12,709	49,144	87,698	104,331
Females	123,837	51	544	1,575	3,809	8,476	20,800	33,291	55,292
Esophagus									
Males	36,777	0	0	42	151	795	4,550	12,056	19,184
Females	10,912	0	0	20	65	253	1,097	3,206	6,272
Stomach									
Males	66,182	0	24	166	855	2,646	8,956	17,838	35,697
Females	50,343	0	34	194	930	2,690	7,429	12,178	26,888
Colon & Rectum									
Males	673,580	0	496	1,677	7,391	26,870	97,594	174,856	364,694
Females	674,507	23	682	2,187	7,535	26,276	87,486	150,342	399,977
Liver & Intrahep									
Males	62,044	655	798	587	548	1,709	10,458	29,467	17,822
Females	27,905	590	662	429	612	1,187	4,084	9,773	10,570
Pancreas									
Males	39,194	15	73	94	564	1,763	6,302	12,922	17,461
Females	39,775	0	94	402	863	2,421	6,224	11,571	18,201
Larynx									
Males	78,873	5	0	95	280	1,443	8,601	22,512	45,936
Females	17,359	0	8	38	170	659	2,894	5,328	8,262
Lung & Bronchus									
Males	248,102	68	114	402	1,276	4,402	23,436	68,436	149,967
Females	310,148	76	61	490	1,539	5,870	32,698	79,250	190,163
Melanoma of the Skin									
Males	637,311	46	604	4,254	16,376	39,626	99,300	171,806	305,299
Females	607,965	117	750	7,851	32,663	66,779	126,153	154,077	219,573

^a U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 1.22 - continued
 U.S. Complete Prevalence Counts, Invasive Cancers Only, January 1, 2017^a
 By Age at Prevalence

Site/Sex	Age at Prevalence								
	All Ages ^c	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+
Breast									
Males	20,067	0	0	4	165	519	2,262	4,978	12,140
Females	3,577,264	16	24	3,230	40,990	208,462	607,256	993,294	1,723,992
Cervix									
Females	291,704	0	41	1,728	14,721	40,501	66,065	73,541	95,106
Corpus & Uterus, NOS									
Females	793,846	6	14	838	7,570	29,736	102,263	234,589	418,829
Ovary ^d									
Females	233,364	83	1,178	4,391	8,781	19,078	45,975	66,047	87,831
Prostate									
Males	3,170,339	24	52	62	160	12,636	211,872	862,584	2,082,949
Urinary Bladder									
Males	535,940	84	102	592	2,304	8,502	39,063	120,315	364,978
Females	176,673	41	66	252	1,015	2,920	13,121	36,108	123,151
Kidney & Renal Pelvis									
Males	341,611	1,528	2,135	2,586	9,504	22,714	56,901	96,822	149,421
Females	216,412	1,787	2,512	3,256	6,978	15,461	34,092	55,594	96,732
Hodgkin Lymphoma									
Males	110,766	177	2,445	10,164	15,563	21,243	26,759	21,198	13,218
Females	104,765	51	1,761	9,008	16,706	20,866	25,039	18,466	12,868
Non-Hodgkin Lymphoma									
Males	381,435	1,018	4,007	8,235	14,539	27,966	61,937	98,040	165,695
Females	338,396	508	1,908	4,789	10,313	21,172	49,161	85,062	165,484
Myeloma									
Males	77,901	0	16	71	715	3,571	11,603	24,109	37,814
Females	62,878	3	17	59	457	2,739	9,316	19,330	30,957
Leukemia									
Males	247,369	6,938	15,759	17,357	13,215	17,531	32,152	54,022	90,393
Females	187,613	6,288	12,094	14,087	11,579	14,414	23,064	35,985	70,102
Acute Lymphocytic Leuk									
Males	54,552	5,780	13,274	13,580	8,828	7,000	3,705	1,625	760
Females	45,460	5,211	10,348	10,530	7,782	5,730	3,314	1,563	982

^a U.S. 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 areas not including the Alaska Natives Registry (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, Rural Georgia, San Jose-Monterey, and Los Angeles) and 1/1/2017 U.S. population estimates based on the average of 2016 and 2017 population estimates from the U.S. Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^c Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

Table 2.21
All Cancer Sites (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	4,863,591	3,678,954	2,671,940	1,874,577	1,156,722	14,245,784	1,515,155	15,760,939
	Males	2,338,455	1,857,458	1,307,418	852,831	477,140	6,833,302	397,509	7,230,811
	Females	2,525,136	1,821,495	1,364,523	1,021,746	679,582	7,412,482	1,117,646	8,530,128
White	Both Sexes	4,024,750	3,103,763	2,301,691	1,639,332	1,019,739	12,089,276	1,304,407	13,393,683
	Males	1,927,986	1,556,489	1,120,549	741,727	420,910	5,767,660	356,439	6,124,100
	Females	2,096,765	1,547,275	1,181,142	897,605	598,830	6,321,616	947,968	7,269,584
Black	Both Sexes	522,353	366,426	243,349	153,030	87,254	1,372,412	107,632	1,480,045
	Males	258,109	197,693	128,021	76,937	38,045	698,805	20,401	719,206
	Females	264,244	168,733	115,328	76,093	49,209	673,608	87,231	760,839
Asian/ Pacific Islander	Both Sexes	183,298	121,582	80,129	51,196	29,176	465,381	+	+
	Males	72,929	49,034	31,005	17,917	9,032	179,916	+	+
	Females	110,369	72,548	49,124	33,279	20,144	285,465	+	+
Hispanic	Both Sexes	408,638	276,391	184,454	116,896	68,716	1,055,094	+	+
	Males	177,231	127,177	83,223	49,354	25,903	462,888	+	+
	Females	231,407	149,214	101,232	67,542	42,812	592,206	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	4.3954	0.0901	0.2070	0.4041	0.9211	2.1986	5.0523	10.5439	18.5788	22.1076	3.7298
	Males	4.2813	0.0920	0.2200	0.3959	0.7363	1.4994	3.9928	10.6625	22.1101	29.8954	3.9647
	Females	4.5060	0.0881	0.1934	0.4127	1.1074	2.8862	6.0653	10.4365	15.6244	17.2583	3.6235
White	Both Sexes	4.7774	0.0947	0.2237	0.4462	1.0025	2.3143	5.1610	10.6316	18.8503	22.5479	3.8150
	Males	4.5989	0.0958	0.2385	0.4391	0.8084	1.5833	3.9945	10.4705	21.9382	29.9112	3.9716
	Females	4.9527	0.0935	0.2081	0.4537	1.2035	3.0536	6.3009	10.7809	16.2101	17.8801	3.7752
Black	Both Sexes	3.0132	0.0672	0.1434	0.2520	0.6091	1.6838	4.5141	10.4660	17.5131	18.6314	3.3375
	Males	3.1967	0.0714	0.1455	0.2433	0.4611	1.1542	4.1869	12.7224	24.8331	29.8122	4.1795
	Females	2.8439	0.0629	0.1412	0.2608	0.7458	2.1530	4.7992	8.6631	12.3947	13.0482	2.8361
Asian/ Pacific Islander	Both Sexes	2.2316	0.0756	0.1492	0.2405	0.5355	1.5093	3.5040	6.7079	10.7417	13.4818	2.3412
	Males	1.7996	0.0780	0.1624	0.2220	0.3636	0.7925	2.0939	5.5224	11.5436	17.2364	2.1409
	Females	2.6294	0.0732	0.1358	0.2591	0.6920	2.1434	4.7256	7.6631	10.0999	11.0339	2.5440
Hispanic	Both Sexes	1.8149	0.0836	0.1966	0.3481	0.6952	1.5731	3.5145	7.3612	12.8691	15.3187	2.6454
	Males	1.5761	0.0868	0.2121	0.3525	0.5450	0.9735	2.4303	6.7974	15.3010	21.5215	2.7366
	Females	2.0588	0.0802	0.1805	0.3433	0.8587	2.1895	4.5874	7.8620	10.9951	11.4686	2.6693

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 3.21
Brain and Other Nervous System (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	47,697	27,833	22,588	17,797	14,239	130,154	38,340	168,494	
	Males	26,219	14,573	11,477	9,236	7,516	69,020	17,798	86,818	
	Females	21,478	13,261	11,111	8,561	6,723	61,134	20,542	81,676	
White	Both Sexes	41,008	23,749	19,674	15,513	12,260	112,203	36,908	149,112	
	Males	22,644	12,527	10,192	8,084	6,470	59,917	18,497	78,415	
	Females	18,365	11,221	9,483	7,428	5,789	52,286	18,411	70,697	
Black	Both Sexes	3,872	2,516	1,840	1,506	1,239	10,973	4,369	15,342	
	Males	2,103	1,141	751	772	632	5,398	1,702	7,099	
	Females	1,769	1,375	1,089	734	608	5,575	2,667	8,242	
Asian/ Pacific Islander	Both Sexes	1,793	981	731	495	375	4,376	+	+	
	Males	926	534	326	230	195	2,212	+	+	
	Females	867	446	405	266	180	2,163	+	+	
Hispanic	Both Sexes	5,566	3,806	2,893	2,178	1,427	15,870	+	+	
	Males	2,933	2,021	1,520	1,160	703	8,338	+	+	
	Females	2,633	1,785	1,372	1,018	724	7,532	+	+	

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0402	0.0155	0.0352	0.0426	0.0429	0.0436	0.0512	0.0506	0.0452	0.0286	0.0391
	Males	0.0432	0.0149	0.0374	0.0455	0.0450	0.0478	0.0547	0.0579	0.0500	0.0354	0.0421
	Females	0.0372	0.0162	0.0330	0.0396	0.0408	0.0395	0.0479	0.0441	0.0412	0.0244	0.0363
White	Both Sexes	0.0443	0.0166	0.0386	0.0473	0.0475	0.0488	0.0570	0.0547	0.0486	0.0296	0.0430
	Males	0.0478	0.0157	0.0412	0.0510	0.0493	0.0525	0.0611	0.0621	0.0539	0.0371	0.0461
	Females	0.0410	0.0175	0.0358	0.0433	0.0456	0.0450	0.0531	0.0479	0.0442	0.0248	0.0400
Black	Both Sexes	0.0241	0.0114	0.0239	0.0290	0.0301	0.0245	0.0229	0.0293	0.0243	0.0215	0.0241
	Males	0.0247	0.0118	0.0241	0.0295	0.0299	0.0285	0.0200	0.0351	0.0230	0.0203	0.0248
	Females	0.0235	0.0109	0.0236	0.0286	0.0303	0.0209	0.0256	0.0248	0.0252	0.0221	0.0234
Asian/ Pacific Islander	Both Sexes	0.0210	0.0099	0.0213	0.0215	0.0196	0.0219	0.0287	0.0260	0.0236	0.0158	0.0207
	Males	0.0221	0.0096	0.0229	0.0197	0.0226	0.0242	0.0316	0.0274	0.0265	0.0158	0.0220
	Females	0.0199	0.0102	0.0197	0.0232	0.0170	0.0198	0.0262	0.0249	0.0213	0.0158	0.0195
Hispanic	Both Sexes	0.0273	0.0124	0.0253	0.0281	0.0250	0.0324	0.0422	0.0417	0.0382	0.0227	0.0286
	Males	0.0284	0.0111	0.0274	0.0292	0.0244	0.0355	0.0466	0.0442	0.0379	0.0266	0.0300
	Females	0.0262	0.0137	0.0232	0.0270	0.0256	0.0293	0.0378	0.0394	0.0385	0.0203	0.0273

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 4.24
Cancer of the Breast (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	1,038,322	802,756	618,582	487,569	310,008	3,257,238		340,094	3,597,331
	Males	8,131	5,042	2,792	2,007	1,109	19,080		987	20,067
	Females	1,030,192	797,714	615,791	485,562	308,899	3,238,158		339,106	3,577,264
White	Both Sexes	858,031	679,619	535,262	429,063	274,298	2,776,273		302,447	3,062,980
	Males	6,500	4,289	2,354	1,679	918	15,740		+	+
	Females	851,531	675,330	532,908	427,384	273,381	2,760,533		302,447	3,062,980
Black	Both Sexes	115,147	78,960	54,273	37,362	23,743	309,485		28,817	335,782
	Males	1,283	573	329	239	96	2,520		+	+
	Females	113,864	78,387	53,944	37,124	23,647	306,966		28,817	335,782
Asian/ Pacific Islander	Both Sexes	49,457	34,063	23,166	16,432	9,005	132,123		+	+
	Males	254	103	69	35	30	492		+	+
	Females	49,202	33,960	23,097	16,397	8,975	131,631		+	+
Hispanic	Both Sexes	86,858	58,758	40,282	27,023	15,667	228,587		+	+
	Males	475	227	140	65	29	936		+	+
	Females	86,383	58,530	40,142	26,957	15,638	227,651		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	1.0050	0.0000	0.0001	0.0071	0.0960	0.5147	1.3812	2.5724	4.1260	4.8849	0.8375
	Males	0.0120	-	-	-	0.0008	0.0026	0.0106	0.0281	0.0676	0.1024	0.0112
	Females	1.9685	0.0001	0.0001	0.0146	0.1920	1.0183	2.6916	4.8744	7.5215	7.8628	1.5400
White	Both Sexes	1.0971	0.0001	0.0001	0.0072	0.0931	0.5157	1.3985	2.6249	4.2635	5.0495	0.8556
	Males	0.0126	-	-	-	0.0006	0.0022	0.0093	0.0268	0.0672	0.1031	0.0108
	Females	2.1628	0.0001	0.0002	0.0148	0.1888	1.0351	2.7559	5.0320	7.8513	8.1852	1.5891
Black	Both Sexes	0.6795	-	-	0.0071	0.1091	0.4963	1.2734	2.3191	3.4736	4.0839	0.7445
	Males	0.0115	-	-	-	0.0011	0.0045	0.0197	0.0428	0.0885	0.1121	0.0151
	Females	1.2960	-	-	0.0143	0.2089	0.9320	2.3657	4.1381	5.8406	6.0672	1.2856
Asian/ Pacific Islander	Both Sexes	0.6336	-	-	0.0061	0.0906	0.5061	1.2848	2.1237	2.7688	2.8808	0.6486
	Males	0.0049	-	-	-	0.0016	0.0018	0.0063	0.0151	0.0296	0.0533	0.0059
	Females	1.2125	-	-	0.0119	0.1716	0.9522	2.3923	3.8225	4.9613	4.7243	1.1674
Hispanic	Both Sexes	0.3932	-	0.0001	0.0058	0.0742	0.3744	0.9760	1.8407	2.7609	2.9562	0.5753
	Males	0.0032	-	-	-	0.0010	0.0024	0.0043	0.0141	0.0332	0.0573	0.0059
	Females	0.7914	-	0.0002	0.0121	0.1539	0.7567	1.9377	3.4629	4.8629	4.7556	1.0565

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 5.15
Cancer of the Cervix Uteri (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>								
All Races	43,448	37,001	35,416	37,194	34,102	187,161	104,544	291,704
White	34,188	30,114	29,094	30,785	28,686	152,866	90,098	242,964
Black	5,377	4,126	4,064	3,976	3,233	20,775	13,989	34,764
Asian/Pacific Islander	2,561	1,817	1,631	1,589	1,400	8,999	+	+
Hispanic	8,097	7,082	7,030	6,680	5,493	34,382	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^c
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races	0.1138	-	0.0002	0.0078	0.0690	0.1947	0.2501	0.2282	0.1871	0.1341	0.1013
White	0.1198	-	0.0002	0.0082	0.0754	0.2109	0.2595	0.2262	0.1790	0.1222	0.1048
Black	0.0877	-	0.0003	0.0063	0.0492	0.1371	0.2069	0.2218	0.2120	0.1881	0.0875
Asian/Pacific Islander	0.0829	-	-	0.0042	0.0316	0.1053	0.1774	0.2269	0.2410	0.2093	0.0789
Hispanic	0.1195	-	0.0004	0.0075	0.0779	0.2125	0.3530	0.3956	0.3831	0.3049	0.1466

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 6.28
Cancer of the Colon and Rectum (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	454,973	315,517	232,226	156,277	86,705	1,245,698	102,389	1,348,087
	Males	235,008	159,606	115,821	77,858	42,445	630,738	42,841	673,580
	Females	219,965	155,912	116,405	78,419	44,259	614,960	59,547	674,507
White	Both Sexes	367,700	258,195	193,427	132,779	73,607	1,025,709	87,047	1,112,756
	Males	191,130	131,805	98,283	66,954	36,302	524,475	36,781	561,256
	Females	176,570	126,390	95,144	65,825	37,305	501,234	50,266	551,500
Black	Both Sexes	55,497	35,839	25,364	15,527	8,694	140,921	9,178	150,100
	Males	26,931	16,527	10,839	6,872	3,947	65,117	3,646	68,763
	Females	28,567	19,312	14,524	8,654	4,747	75,805	5,532	81,336
Asian/ Pacific Islander	Both Sexes	22,099	14,831	9,904	5,916	3,390	56,140	+	+
	Males	11,784	7,575	4,848	2,904	1,655	28,766	+	+
	Females	10,315	7,256	5,055	3,012	1,735	27,374	+	+
Hispanic	Both Sexes	41,755	25,151	15,479	8,853	4,483	95,721	+	+
	Males	21,730	13,169	7,820	4,512	2,259	49,490	+	+
	Females	20,025	11,982	7,659	4,341	2,225	46,231	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.3843	0.0001	0.0028	0.0085	0.0348	0.1296	0.4123	0.8410	1.6146	2.8343	0.3225
	Males	0.3952	-	0.0023	0.0072	0.0343	0.1324	0.4471	0.9597	1.8925	3.2339	0.3663
	Females	0.3738	0.0001	0.0033	0.0099	0.0352	0.1268	0.3791	0.7336	1.3822	2.5855	0.2878
White	Both Sexes	0.4053	0.0001	0.0033	0.0095	0.0358	0.1295	0.3974	0.8025	1.5836	2.8550	0.3169
	Males	0.4182	-	0.0027	0.0080	0.0353	0.1323	0.4322	0.9196	1.8658	3.2375	0.3603
	Females	0.3927	0.0002	0.0038	0.0111	0.0364	0.1267	0.3633	0.6939	1.3423	2.6125	0.2818
Black	Both Sexes	0.3094	-	0.0010	0.0044	0.0318	0.1292	0.4560	1.0428	1.8389	2.7245	0.3522
	Males	0.2979	-	0.0008	0.0035	0.0331	0.1251	0.4732	1.1558	2.0556	3.2678	0.3938
	Females	0.3200	-	0.0013	0.0053	0.0307	0.1327	0.4411	0.9526	1.6874	2.4532	0.3257
Asian/ Pacific Islander	Both Sexes	0.2692	-	0.0013	0.0043	0.0223	0.1071	0.4007	0.8267	1.4672	2.3469	0.2900
	Males	0.2877	-	0.0015	0.0044	0.0200	0.1194	0.4606	0.9748	1.7651	2.7030	0.3391
	Females	0.2521	-	0.0011	0.0041	0.0244	0.0962	0.3488	0.7075	1.2287	2.1147	0.2517
Hispanic	Both Sexes	0.1647	0.0001	0.0023	0.0057	0.0265	0.0968	0.3293	0.7252	1.3399	2.0475	0.2583
	Males	0.1685	-	0.0015	0.0046	0.0248	0.0974	0.3475	0.8308	1.6303	2.5483	0.3032
	Females	0.1607	0.0001	0.0031	0.0068	0.0283	0.0962	0.3113	0.6314	1.1161	1.7367	0.2251

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 7.15
Cancer of the Corpus and Uterus, NOS (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>								
All Races	233,904	168,435	119,459	89,731	57,498	669,026	124,819	793,846
White	196,349	145,978	106,288	81,357	52,694	582,667	105,108	687,775
Black	22,770	12,972	7,262	4,413	2,428	49,846	5,287	55,132
Asian/Pacific Islander	10,432	7,010	4,449	2,905	1,752	26,547	+	+
Hispanic	22,103	13,197	8,530	5,147	3,121	52,097	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^c
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races	0.4067	0.0000	0.0001	0.0038	0.0354	0.1445	0.4503	1.1561	1.6950	1.5347	0.3121
White	0.4565	-	0.0001	0.0036	0.0354	0.1485	0.4705	1.2151	1.7930	1.6386	0.3281
Black	0.2104	0.0002	-	0.0045	0.0288	0.0961	0.2669	0.8127	1.1765	0.9022	0.2085
Asian/Pacific Islander	0.2445	-	-	0.0043	0.0365	0.1592	0.4960	0.9042	0.9397	0.7160	0.2300
Hispanic	0.1811	-	-	0.0059	0.0520	0.1674	0.4125	0.8725	1.1305	0.8464	0.2394

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 8.21
Cancer of the Esophagus (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	27,474	9,941	5,094	2,733	970	46,212	1,478	47,690	
	Males	21,530	7,591	3,804	2,132	744	35,800	978	36,777	
	Females	5,944	2,350	1,290	601	227	10,412	500	10,912	
White	Both Sexes	24,528	9,166	4,657	2,491	805	41,646	1,177	42,823	
	Males	19,465	7,136	3,561	1,992	639	32,792	812	33,605	
	Females	5,063	2,031	1,096	499	166	8,854	364	9,218	
Black	Both Sexes	1,946	502	291	168	117	3,025	185	3,209	
	Males	1,334	260	147	98	71	1,909	78	1,988	
	Females	613	242	144	71	46	1,116	106	1,222	
Asian/ Pacific Islander	Both Sexes	678	176	88	55	23	1,020	+	+	
	Males	508	107	52	37	18	721	+	+	
	Females	170	69	36	19	5	299	+	+	
Hispanic	Both Sexes	1,481	454	166	103	58	2,262	+	+	
	Males	1,195	359	132	97	48	1,831	+	+	
	Females	286	95	34	6	11	431	+	+	

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0143	-	-	0.0001	0.0005	0.0026	0.0128	0.0407	0.0739	0.0734	0.0117
	Males	0.0224	-	-	0.0002	0.0007	0.0039	0.0211	0.0679	0.1276	0.1357	0.0201
	Females	0.0063	-	-	0.0001	0.0003	0.0012	0.0048	0.0161	0.0290	0.0346	0.0048
White	Both Sexes	0.0165	-	-	0.0001	0.0005	0.0028	0.0135	0.0439	0.0804	0.0771	0.0126
	Males	0.0261	-	-	0.0002	0.0007	0.0045	0.0223	0.0737	0.1386	0.1439	0.0217
	Females	0.0069	-	-	0.0000	0.0003	0.0011	0.0049	0.0163	0.0307	0.0347	0.0049
Black	Both Sexes	0.0066	-	-	0.0001	0.0007	0.0020	0.0110	0.0279	0.0342	0.0441	0.0072
	Males	0.0087	-	-	-	0.0009	0.0016	0.0183	0.0389	0.0540	0.0684	0.0108
	Females	0.0047	-	-	0.0002	0.0005	0.0023	0.0047	0.0191	0.0204	0.0319	0.0046
Asian/ Pacific Islander	Both Sexes	0.0049	-	-	0.0002	-	0.0013	0.0059	0.0159	0.0320	0.0420	0.0053
	Males	0.0072	-	-	-	-	0.0016	0.0091	0.0288	0.0481	0.0690	0.0085
	Females	0.0028	-	-	-	-	0.0010	0.0031	0.0056	0.0192	0.0243	0.0029
Hispanic	Both Sexes	0.0039	-	-	0.0001	0.0001	0.0021	0.0063	0.0198	0.0391	0.0413	0.0063
	Males	0.0062	-	-	0.0002	0.0001	0.0034	0.0109	0.0340	0.0741	0.0789	0.0114
	Females	0.0015	-	-	-	0.0002	0.0007	0.0018	0.0072	0.0121	0.0179	0.0022

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 9.21
Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	37,871	34,834	31,045	26,309	22,612	152,671	62,860	215,531	
	Males	21,103	18,693	15,900	13,296	11,208	80,200	30,566	110,766	
	Females	16,768	16,140	15,145	13,013	11,404	72,471	32,294	104,765	
White	Both Sexes	30,738	28,984	26,160	22,837	19,902	128,619	59,871	188,491	
	Males	17,198	15,626	13,547	11,517	9,940	67,828	30,377	98,206	
	Females	13,540	13,358	12,613	11,319	9,961	60,791	29,494	90,285	
Black	Both Sexes	5,116	4,343	3,700	2,695	2,188	18,042	5,210	23,252	
	Males	2,779	2,296	1,722	1,327	1,040	9,164	3,405	12,569	
	Females	2,337	2,047	1,978	1,368	1,148	8,878	1,806	10,683	
Asian/ Pacific Islander	Both Sexes	1,133	963	766	466	286	3,614	+	+	
	Males	615	485	373	256	103	1,831	+	+	
	Females	518	478	392	211	183	1,782	+	+	
Hispanic	Both Sexes	4,969	4,134	3,161	2,590	1,640	16,495	+	+	
	Males	2,761	2,163	1,740	1,422	897	8,982	+	+	
	Females	2,208	1,971	1,421	1,168	744	7,512	+	+	

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0471	0.0006	0.0101	0.0423	0.0733	0.0830	0.0674	0.0535	0.0491	0.0396	0.0467
	Males	0.0502	0.0009	0.0114	0.0438	0.0699	0.0854	0.0755	0.0644	0.0598	0.0485	0.0497
	Females	0.0441	0.0003	0.0086	0.0406	0.0767	0.0807	0.0596	0.0436	0.0402	0.0341	0.0441
White	Both Sexes	0.0508	0.0005	0.0103	0.0460	0.0798	0.0894	0.0711	0.0560	0.0522	0.0426	0.0501
	Males	0.0541	0.0007	0.0112	0.0481	0.0751	0.0917	0.0789	0.0668	0.0628	0.0520	0.0528
	Females	0.0476	0.0003	0.0093	0.0437	0.0847	0.0871	0.0635	0.0460	0.0432	0.0367	0.0478
Black	Both Sexes	0.0396	0.0009	0.0098	0.0339	0.0622	0.0770	0.0651	0.0504	0.0367	0.0233	0.0414
	Males	0.0419	0.0018	0.0122	0.0322	0.0615	0.0769	0.0760	0.0629	0.0499	0.0329	0.0447
	Females	0.0375	-	0.0073	0.0356	0.0629	0.0771	0.0556	0.0404	0.0274	0.0184	0.0387
Asian/ Pacific Islander	Both Sexes	0.0173	0.0005	0.0077	0.0202	0.0291	0.0247	0.0186	0.0163	0.0159	0.0107	0.0165
	Males	0.0183	0.0008	0.0106	0.0228	0.0300	0.0231	0.0193	0.0165	0.0226	0.0106	0.0177
	Females	0.0164	-	0.0047	0.0175	0.0283	0.0260	0.0179	0.0161	0.0105	0.0108	0.0155
Hispanic	Both Sexes	0.0284	0.0005	0.0088	0.0312	0.0461	0.0453	0.0408	0.0444	0.0490	0.0409	0.0315
	Males	0.0306	0.0008	0.0097	0.0336	0.0451	0.0485	0.0459	0.0557	0.0573	0.0574	0.0347
	Females	0.0261	0.0002	0.0078	0.0287	0.0472	0.0421	0.0357	0.0343	0.0426	0.0306	0.0287

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 10.15
Kaposi SarcomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	8,085	7,440	6,099	5,547	7,325	34,496	+	+
	Males	7,350	6,933	5,862	5,355	7,156	32,656	+	+
	Females	735	507	237	192	169	1,840	+	+
White	Both Sexes	4,870	5,023	4,737	4,064	6,115	24,808	+	+
	Males	4,363	4,628	4,573	3,906	5,985	23,456	+	+
	Females	507	394	164	158	130	1,353	+	+
Black	Both Sexes	2,358	1,882	1,066	1,078	747	7,131	+	+
	Males	2,204	1,817	1,014	1,061	716	6,813	+	+
	Females	153	64	52	17	30	317	+	+
Asian/ Pacific Islander	Both Sexes	159	133	91	61	66	510	+	+
	Males	146	128	88	61	66	489	+	+
	Females	13	5	3	0	0	21	+	+
Hispanic	Both Sexes	1,260	1,162	1,000	873	999	5,294	+	+
	Males	1,132	1,034	969	836	982	4,953	+	+
	Females	128	127	31	38	16	341	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0106	0.0000	0.0000	0.0015	0.0069	0.0154	0.0280	0.0191	0.0137	0.0206	0.0096
	Males	0.0205	0.0001	0.0000	0.0030	0.0133	0.0303	0.0558	0.0389	0.0266	0.0380	0.0189
	Females	0.0011	-	0.0000	-	0.0003	0.0006	0.0015	0.0012	0.0029	0.0097	0.0009
White	Both Sexes	0.0098	0.0000	0.0000	0.0005	0.0038	0.0123	0.0264	0.0185	0.0139	0.0208	0.0083
	Males	0.0187	0.0001	-	0.0011	0.0073	0.0241	0.0522	0.0375	0.0265	0.0385	0.0162
	Females	0.0011	-	0.0001	-	0.0001	0.0003	0.0012	0.0009	0.0031	0.0096	0.0008
Black	Both Sexes	0.0157	0.0001	0.0001	0.0061	0.0242	0.0308	0.0387	0.0232	0.0107	0.0121	0.0162
	Males	0.0312	0.0003	0.0003	0.0122	0.0487	0.0631	0.0798	0.0492	0.0236	0.0234	0.0333
	Females	0.0013	-	-	-	0.0016	0.0022	0.0029	0.0023	0.0016	0.0065	0.0014
Asian/ Pacific Islander	Both Sexes	0.0024	-	-	0.0003	0.0016	0.0047	0.0054	0.0052	0.0040	0.0061	0.0024
	Males	0.0049	-	-	0.0006	0.0033	0.0099	0.0112	0.0110	0.0090	0.0111	0.0051
	Females	0.0002	-	-	-	-	-	0.0005	0.0006	-	0.0029	0.0002
Hispanic	Both Sexes	0.0091	0.0001	-	0.0010	0.0068	0.0163	0.0330	0.0219	0.0199	0.0408	0.0115
	Males	0.0169	0.0001	-	0.0019	0.0129	0.0315	0.0641	0.0436	0.0390	0.0634	0.0218
	Females	0.0012	-	-	-	0.0001	0.0006	0.0022	0.0027	0.0052	0.0267	0.0017

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 11.21
Cancer of the Kidney And Renal Pelvis (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	212,636	141,539	83,534	43,716	24,788	506,213		51,810	558,023
	Males	134,586	87,358	49,888	25,275	14,230	311,337		30,274	341,611
	Females	78,050	54,181	33,646	18,441	10,558	194,877		21,536	216,412
White	Both Sexes	176,220	118,117	71,682	37,629	21,457	425,105		49,035	474,141
	Males	112,161	73,194	42,881	22,104	12,612	262,951		25,316	288,267
	Females	64,059	44,924	28,801	15,526	8,845	162,154		23,720	185,874
Black	Both Sexes	26,233	17,241	8,706	4,662	2,580	59,422		7,461	66,884
	Males	16,140	10,254	5,164	2,365	1,186	35,109		3,356	38,465
	Females	10,093	6,987	3,542	2,298	1,393	24,313		4,105	28,418
Asian/ Pacific Islander	Both Sexes	6,373	3,810	1,948	964	466	13,561		+	+
	Males	4,033	2,395	1,127	556	283	8,393		+	+
	Females	2,340	1,415	822	408	183	5,168		+	+
Hispanic	Both Sexes	23,149	13,822	7,079	3,762	1,883	49,696		+	+
	Males	13,393	7,781	3,889	2,073	1,009	28,145		+	+
	Females	9,756	6,041	3,190	1,689	874	21,551		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.1562	0.0082	0.0111	0.0111	0.0209	0.0751	0.1953	0.3985	0.6675	0.6808	0.1316
	Males	0.1951	0.0074	0.0100	0.0095	0.0237	0.0916	0.2520	0.5354	0.9291	0.9964	0.1763
	Females	0.1185	0.0091	0.0123	0.0128	0.0181	0.0589	0.1410	0.2747	0.4487	0.4843	0.0947
White	Both Sexes	0.1680	0.0079	0.0113	0.0114	0.0218	0.0767	0.1978	0.3993	0.6749	0.6931	0.1331
	Males	0.2097	0.0069	0.0104	0.0101	0.0242	0.0915	0.2523	0.5324	0.9363	1.0165	0.1772
	Females	0.1270	0.0089	0.0122	0.0128	0.0194	0.0617	0.1445	0.2760	0.4513	0.4880	0.0960
Black	Both Sexes	0.1305	0.0107	0.0130	0.0129	0.0201	0.0779	0.2066	0.4598	0.7323	0.6668	0.1421
	Males	0.1606	0.0109	0.0103	0.0093	0.0253	0.1015	0.2817	0.6393	1.0502	0.9854	0.1965
	Females	0.1026	0.0105	0.0158	0.0166	0.0152	0.0569	0.1412	0.3163	0.5101	0.5077	0.1028
Asian/ Pacific Islander	Both Sexes	0.0650	0.0045	0.0045	0.0035	0.0092	0.0394	0.0996	0.2053	0.3394	0.3992	0.0686
	Males	0.0840	0.0033	0.0042	0.0031	0.0111	0.0529	0.1381	0.2999	0.4777	0.5589	0.0953
	Females	0.0476	0.0057	0.0048	0.0039	0.0075	0.0276	0.0663	0.1292	0.2287	0.2951	0.0474
Hispanic	Both Sexes	0.0855	0.0059	0.0089	0.0085	0.0206	0.0727	0.1755	0.3850	0.6244	0.6750	0.1251
	Males	0.0958	0.0053	0.0076	0.0058	0.0223	0.0780	0.2070	0.4829	0.8356	0.9388	0.1580
	Females	0.0749	0.0065	0.0102	0.0114	0.0188	0.0672	0.1444	0.2981	0.4617	0.5112	0.0995

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 12.21
Cancer of the Larynx (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	34,735	22,122	13,441	9,727	6,306	86,330	9,901	96,231
	Males	28,491	18,089	10,852	8,018	5,054	70,504	8,368	78,873
	Females	6,244	4,033	2,589	1,709	1,252	15,826	1,533	17,359
White	Both Sexes	28,728	18,791	11,531	8,404	5,399	72,853	7,920	80,773
	Males	23,680	15,422	9,309	6,961	4,327	59,699	6,704	66,403
	Females	5,049	3,369	2,223	1,443	1,071	13,154	1,215	14,370
Black	Both Sexes	4,925	2,662	1,546	1,061	769	10,964	848	11,812
	Males	3,871	2,106	1,247	816	632	8,672	722	9,394
	Females	1,054	556	300	245	137	2,292	126	2,419
Asian/ Pacific Islander	Both Sexes	600	447	259	157	91	1,555	+	+
	Males	516	368	217	137	76	1,315	+	+
	Females	84	78	42	20	15	239	+	+
Hispanic	Both Sexes	2,365	1,519	784	651	317	5,636	+	+
	Males	2,081	1,326	662	522	257	4,848	+	+
	Females	284	193	122	129	60	788	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)									Age-Adjusted ^c	
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0266	0.0000	0.0000	0.0003	0.0010	0.0052	0.0262	0.0741	0.1345	0.1388	0.0218
	Males	0.0442	0.0000	-	0.0004	0.0013	0.0072	0.0401	0.1263	0.2503	0.3053	0.0399
	Females	0.0096	-	0.0000	0.0002	0.0008	0.0032	0.0128	0.0269	0.0376	0.0351	0.0074
White	Both Sexes	0.0288	0.0000	0.0000	0.0003	0.0011	0.0054	0.0276	0.0733	0.1341	0.1402	0.0220
	Males	0.0476	0.0000	-	0.0004	0.0013	0.0070	0.0421	0.1237	0.2474	0.3068	0.0398
	Females	0.0103	-	0.0001	0.0002	0.0009	0.0037	0.0135	0.0266	0.0371	0.0347	0.0075
Black	Both Sexes	0.0241	-	-	0.0003	0.0010	0.0058	0.0260	0.1022	0.1745	0.1535	0.0269
	Males	0.0397	-	-	0.0007	0.0015	0.0104	0.0386	0.1813	0.3472	0.3773	0.0524
	Females	0.0097	-	-	-	0.0005	0.0017	0.0150	0.0390	0.0537	0.0417	0.0094
Asian/ Pacific Islander	Both Sexes	0.0075	-	-	-	0.0007	0.0012	0.0068	0.0231	0.0547	0.0692	0.0082
	Males	0.0132	-	-	-	0.0008	0.0018	0.0125	0.0434	0.1097	0.1423	0.0162
	Females	0.0022	-	-	-	0.0006	0.0006	0.0018	0.0068	0.0106	0.0216	0.0022
Hispanic	Both Sexes	0.0097	-	-	0.0004	0.0007	0.0039	0.0151	0.0457	0.0980	0.1236	0.0159
	Males	0.0165	-	-	0.0004	0.0009	0.0052	0.0248	0.0843	0.2086	0.2780	0.0319
	Females	0.0027	-	-	0.0004	0.0005	0.0026	0.0056	0.0114	0.0129	0.0278	0.0037

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 13.29
LeukemiaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	157,262	105,314	67,081	40,842	27,001	397,501		37,481	434,982
	Males	92,815	61,226	37,439	22,765	15,190	229,436		17,933	247,369
	Females	64,447	44,089	29,642	18,077	11,811	168,065		19,548	187,613
White	Both Sexes	135,982	92,133	59,212	36,221	24,014	347,562		31,583	379,145
	Males	80,710	53,989	33,327	20,247	13,614	201,888		14,337	216,225
	Females	55,272	38,144	25,884	15,974	10,400	145,674		17,246	162,920
Black	Both Sexes	13,034	7,363	4,513	2,574	1,603	29,086		4,141	33,227
	Males	7,121	4,011	2,347	1,288	857	15,624		1,797	17,421
	Females	5,913	3,352	2,166	1,285	746	13,462		2,344	15,806
Asian/ Pacific Islander	Both Sexes	4,198	2,633	1,916	1,184	878	10,809		+	+
	Males	2,395	1,512	985	667	462	6,022		+	+
	Females	1,803	1,121	931	516	416	4,787		+	+
Hispanic	Both Sexes	15,475	10,295	7,211	4,736	3,447	41,164		+	+
	Males	8,703	5,760	4,028	2,528	2,013	23,031		+	+
	Females	6,772	4,536	3,182	2,209	1,434	18,133		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.1226	0.0328	0.0666	0.0660	0.0413	0.0586	0.1107	0.2311	0.4153	0.5334	0.1095
	Males	0.1438	0.0337	0.0738	0.0719	0.0459	0.0680	0.1352	0.2956	0.5483	0.7262	0.1355
	Females	0.1022	0.0319	0.0591	0.0599	0.0367	0.0493	0.0872	0.1728	0.3041	0.4134	0.0878
White	Both Sexes	0.1373	0.0364	0.0744	0.0753	0.0450	0.0611	0.1164	0.2458	0.4398	0.5658	0.1175
	Males	0.1610	0.0372	0.0825	0.0812	0.0503	0.0706	0.1421	0.3122	0.5787	0.7671	0.1445
	Females	0.1141	0.0355	0.0659	0.0691	0.0395	0.0514	0.0914	0.1843	0.3211	0.4382	0.0944
Black	Both Sexes	0.0639	0.0154	0.0346	0.0318	0.0305	0.0484	0.0803	0.1489	0.2568	0.3116	0.0687
	Males	0.0715	0.0146	0.0386	0.0356	0.0304	0.0543	0.0982	0.1866	0.3373	0.4390	0.0846
	Females	0.0568	0.0162	0.0305	0.0279	0.0306	0.0432	0.0647	0.1188	0.2005	0.2479	0.0574
Asian/ Pacific Islander	Both Sexes	0.0518	0.0285	0.0517	0.0448	0.0248	0.0398	0.0587	0.0903	0.1325	0.1418	0.0531
	Males	0.0602	0.0298	0.0552	0.0513	0.0279	0.0471	0.0693	0.1190	0.1671	0.1979	0.0635
	Females	0.0441	0.0272	0.0481	0.0382	0.0220	0.0333	0.0495	0.0672	0.1049	0.1052	0.0446
Hispanic	Both Sexes	0.0708	0.0370	0.0781	0.0779	0.0440	0.0522	0.0764	0.1257	0.2075	0.2243	0.0791
	Males	0.0784	0.0385	0.0877	0.0870	0.0511	0.0619	0.0872	0.1425	0.2363	0.2720	0.0904
	Females	0.0630	0.0355	0.0680	0.0679	0.0363	0.0422	0.0657	0.1108	0.1853	0.1948	0.0687

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 13.30
Acute Lymphocytic Leukemia

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	20,797	16,805	14,080	12,139	10,481	74,301	25,711	100,012
	Males	11,608	9,421	7,933	6,538	5,931	41,431	13,121	54,552
	Females	9,189	7,384	6,147	5,601	4,549	32,870	12,590	45,460
White	Both Sexes	17,431	14,514	12,132	10,722	9,168	63,967	21,903	85,870
	Males	9,864	8,055	6,864	5,736	5,223	35,742	11,323	47,066
	Females	7,566	6,459	5,268	4,986	3,946	28,225	10,579	38,804
Black	Both Sexes	1,646	1,184	984	767	658	5,238	1,580	6,818
	Males	826	758	552	409	345	2,890	553	3,443
	Females	819	425	432	359	312	2,348	1,027	3,375
Asian/ Pacific Islander	Both Sexes	1,086	735	708	475	461	3,465	+	+
	Males	559	407	387	286	255	1,893	+	+
	Females	527	328	321	189	206	1,572	+	+
Hispanic	Both Sexes	6,401	4,726	3,621	2,733	2,321	19,802	+	+
	Males	3,595	2,744	2,093	1,435	1,399	11,266	+	+
	Females	2,805	1,981	1,528	1,298	922	8,535	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0229	0.0273	0.0565	0.0493	0.0161	0.0084	0.0070	0.0066	0.0057	0.0032	0.0240
	Males	0.0260	0.0281	0.0622	0.0549	0.0188	0.0102	0.0077	0.0070	0.0056	0.0036	0.0265
	Females	0.0200	0.0265	0.0506	0.0435	0.0134	0.0065	0.0064	0.0062	0.0058	0.0029	0.0214
White	Both Sexes	0.0253	0.0306	0.0642	0.0574	0.0186	0.0091	0.0076	0.0071	0.0060	0.0030	0.0272
	Males	0.0285	0.0315	0.0707	0.0629	0.0216	0.0115	0.0082	0.0076	0.0059	0.0035	0.0300
	Females	0.0221	0.0297	0.0573	0.0515	0.0156	0.0067	0.0069	0.0065	0.0060	0.0028	0.0244
Black	Both Sexes	0.0115	0.0112	0.0262	0.0204	0.0082	0.0042	0.0038	0.0026	0.0032	0.0034	0.0108
	Males	0.0132	0.0109	0.0299	0.0245	0.0092	0.0029	0.0049	0.0020	0.0033	0.0026	0.0119
	Females	0.0099	0.0114	0.0224	0.0161	0.0074	0.0053	0.0028	0.0031	0.0031	0.0038	0.0097
Asian/ Pacific Islander	Both Sexes	0.0166	0.0228	0.0403	0.0310	0.0076	0.0070	0.0057	0.0055	0.0061	0.0034	0.0170
	Males	0.0189	0.0221	0.0420	0.0373	0.0098	0.0080	0.0063	0.0063	0.0046	0.0042	0.0185
	Females	0.0145	0.0235	0.0385	0.0247	0.0056	0.0062	0.0052	0.0048	0.0073	0.0029	0.0155
Hispanic	Both Sexes	0.0341	0.0321	0.0674	0.0618	0.0197	0.0122	0.0116	0.0109	0.0082	0.0017	0.0299
	Males	0.0384	0.0332	0.0756	0.0699	0.0239	0.0146	0.0128	0.0077	0.0065	-	0.0331
	Females	0.0297	0.0310	0.0589	0.0530	0.0151	0.0096	0.0104	0.0138	0.0095	0.0028	0.0265

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 14.21
Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	59,658	16,682	6,951	2,563	1,124	86,978	2,972	89,950
	Males	42,348	11,786	4,810	1,574	690	61,209	836	62,044
	Females	17,310	4,896	2,141	989	433	25,769	2,137	27,905
White	Both Sexes	44,649	12,441	5,179	1,867	863	65,001	+	+
	Males	31,790	8,787	3,654	1,103	548	45,882	+	+
	Females	12,860	3,654	1,525	764	315	19,119	+	+
Black	Both Sexes	8,690	1,858	571	147	67	11,334	+	+
	Males	6,211	1,311	293	84	18	7,917	+	+
	Females	2,478	547	278	63	50	3,416	+	+
Asian/ Pacific Islander	Both Sexes	4,884	2,010	1,025	455	126	8,501	+	+
	Males	3,325	1,418	732	326	94	5,895	+	+
	Females	1,560	592	293	129	32	2,606	+	+
Hispanic	Both Sexes	8,666	2,428	927	314	188	12,523	+	+
	Males	6,061	1,655	679	167	136	8,699	+	+
	Females	2,605	773	248	147	52	3,825	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0268	0.0031	0.0035	0.0021	0.0021	0.0064	0.0323	0.1052	0.0930	0.0647	0.0213
	Males	0.0383	0.0032	0.0037	0.0024	0.0023	0.0083	0.0487	0.1685	0.1354	0.0970	0.0315
	Females	0.0157	0.0030	0.0032	0.0018	0.0019	0.0046	0.0165	0.0478	0.0575	0.0446	0.0123
White	Both Sexes	0.0257	0.0033	0.0039	0.0023	0.0019	0.0057	0.0299	0.0934	0.0829	0.0576	0.0193
	Males	0.0366	0.0032	0.0042	0.0025	0.0021	0.0074	0.0453	0.1482	0.1198	0.0861	0.0282
	Females	0.0150	0.0034	0.0035	0.0020	0.0018	0.0040	0.0148	0.0427	0.0514	0.0396	0.0113
Black	Both Sexes	0.0249	0.0013	0.0013	0.0009	0.0026	0.0056	0.0306	0.1570	0.1028	0.0507	0.0242
	Males	0.0362	0.0017	0.0013	0.0014	0.0027	0.0063	0.0410	0.2689	0.1651	0.0808	0.0385
	Females	0.0144	0.0008	0.0013	0.0005	0.0026	0.0051	0.0215	0.0677	0.0593	0.0356	0.0134
Asian/ Pacific Islander	Both Sexes	0.0408	0.0039	0.0042	0.0019	0.0027	0.0139	0.0592	0.1541	0.2310	0.2139	0.0426
	Males	0.0590	0.0046	0.0044	0.0020	0.0034	0.0204	0.0986	0.2580	0.3396	0.3139	0.0653
	Females	0.0240	0.0032	0.0040	0.0018	0.0021	0.0082	0.0252	0.0704	0.1442	0.1487	0.0244
Hispanic	Both Sexes	0.0215	0.0037	0.0037	0.0019	0.0013	0.0068	0.0480	0.1359	0.1578	0.0942	0.0303
	Males	0.0296	0.0041	0.0042	0.0020	0.0014	0.0092	0.0752	0.2142	0.2306	0.1261	0.0449
	Females	0.0133	0.0032	0.0033	0.0018	0.0011	0.0044	0.0212	0.0664	0.1018	0.0744	0.0178

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 15.27
Cancer of the Lung And Bronchus (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	309,999	109,572	54,256	28,332	14,971	517,130		41,120	558,250
	Males	141,510	45,588	21,736	11,364	6,138	226,337		21,765	248,102
	Females	168,488	63,984	32,519	16,968	8,833	290,793		19,355	310,148
White	Both Sexes	258,339	93,440	46,822	24,613	12,939	436,153		24,670	460,823
	Males	116,834	38,583	18,374	9,649	5,184	188,624		11,651	200,275
	Females	141,505	54,857	28,448	14,964	7,755	247,530		13,019	260,548
Black	Both Sexes	36,049	11,452	5,411	2,605	1,499	57,017		2,802	59,819
	Males	17,097	4,951	2,443	1,198	686	26,375		1,431	27,806
	Females	18,952	6,501	2,968	1,407	813	30,642		1,371	32,013
Asian/ Pacific Islander	Both Sexes	12,447	3,592	1,679	846	379	18,944		+	+
	Males	6,106	1,598	791	397	192	9,084		+	+
	Females	6,341	1,994	889	450	187	9,860		+	+
Hispanic	Both Sexes	14,069	4,565	2,209	1,153	581	22,577		+	+
	Males	6,217	1,853	926	451	244	9,692		+	+
	Females	7,852	2,712	1,282	702	337	12,885		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.1596	0.0004	0.0004	0.0020	0.0066	0.0250	0.1250	0.3820	0.8972	0.9877	0.1332
	Males	0.1418	0.0003	0.0005	0.0017	0.0059	0.0216	0.1058	0.3676	0.8840	1.0532	0.1308
	Females	0.1768	0.0004	0.0003	0.0022	0.0072	0.0285	0.1434	0.3950	0.9082	0.9470	0.1361
White	Both Sexes	0.1724	0.0003	0.0005	0.0021	0.0069	0.0250	0.1196	0.3744	0.9105	1.0089	0.1336
	Males	0.1504	0.0002	0.0006	0.0016	0.0061	0.0211	0.0990	0.3515	0.8760	1.0544	0.1284
	Females	0.1939	0.0004	0.0004	0.0026	0.0077	0.0291	0.1398	0.3956	0.9400	0.9801	0.1389
Black	Both Sexes	0.1252	0.0007	0.0003	0.0017	0.0051	0.0249	0.1695	0.4765	0.9086	0.8480	0.1408
	Males	0.1207	0.0008	0.0005	0.0023	0.0055	0.0248	0.1530	0.5204	1.0559	1.0662	0.1584
	Females	0.1294	0.0005	-	0.0012	0.0046	0.0249	0.1839	0.4414	0.8056	0.7391	0.1300
Asian/ Pacific Islander	Both Sexes	0.0908	-	-	0.0012	0.0056	0.0238	0.0995	0.2915	0.6085	0.7913	0.0997
	Males	0.0909	-	-	0.0013	0.0038	0.0200	0.0972	0.3137	0.6950	0.9516	0.1109
	Females	0.0908	-	-	0.0010	0.0072	0.0271	0.1016	0.2737	0.5393	0.6868	0.0917
Hispanic	Both Sexes	0.0388	0.0001	0.0002	0.0015	0.0042	0.0131	0.0543	0.1617	0.4417	0.5334	0.0653
	Males	0.0330	0.0001	0.0002	0.0011	0.0031	0.0109	0.0454	0.1456	0.4429	0.6119	0.0655
	Females	0.0448	0.0002	0.0002	0.0019	0.0054	0.0154	0.0631	0.1760	0.4408	0.4847	0.0661

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 16.21
Melanoma of the Skin (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	357,221	257,387	195,778	147,197	102,106	1,059,689	185,587	1,245,276
	Males	201,451	137,918	99,848	72,153	48,666	560,036	77,275	637,311
	Females	155,769	119,469	95,930	75,045	53,440	499,653	108,312	607,965
White	Both Sexes	338,091	247,964	189,334	140,935	96,370	1,012,695	174,876	1,187,570
	Males	191,139	133,340	96,697	69,218	46,057	536,451	73,511	609,962
	Females	146,952	114,624	92,637	71,718	50,313	476,243	101,364	577,608
Black	Both Sexes	1,249	824	615	513	370	3,570	483	4,053
	Males	576	334	238	210	199	1,557	213	1,770
	Females	673	490	377	303	171	2,014	269	2,283
Asian/ Pacific Islander	Both Sexes	1,076	695	563	405	217	2,956	+	+
	Males	517	318	239	145	96	1,315	+	+
	Females	559	377	324	259	121	1,641	+	+
Hispanic	Both Sexes	8,012	5,025	3,731	2,985	1,876	21,629	+	+
	Males	3,438	2,009	1,236	1,028	623	8,333	+	+
	Females	4,574	3,016	2,496	1,956	1,254	13,296	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.3270	0.0004	0.0032	0.0267	0.1128	0.2479	0.4638	0.7602	1.1710	1.4053	0.2811
	Males	0.3509	0.0002	0.0028	0.0184	0.0756	0.1911	0.4346	0.8815	1.5924	2.1908	0.3226
	Females	0.3037	0.0006	0.0037	0.0354	0.1502	0.3037	0.4918	0.6504	0.8185	0.9162	0.2544
White	Both Sexes	0.4002	0.0005	0.0038	0.0332	0.1393	0.3009	0.5474	0.8794	1.3218	1.5687	0.3262
	Males	0.4277	0.0003	0.0034	0.0228	0.0927	0.2275	0.5060	1.0087	1.7778	2.4257	0.3671
	Females	0.3731	0.0007	0.0042	0.0442	0.1876	0.3752	0.5879	0.7595	0.9318	1.0255	0.3009
Black	Both Sexes	0.0078	-	0.0009	0.0007	0.0041	0.0077	0.0112	0.0211	0.0376	0.0551	0.0089
	Males	0.0071	-	0.0003	0.0007	0.0032	0.0045	0.0109	0.0228	0.0446	0.0764	0.0094
	Females	0.0085	-	0.0016	0.0007	0.0049	0.0106	0.0115	0.0197	0.0327	0.0445	0.0088
Asian/ Pacific Islander	Both Sexes	0.0142	0.0008	0.0012	0.0024	0.0060	0.0158	0.0228	0.0358	0.0570	0.0668	0.0146
	Males	0.0132	0.0005	0.0008	0.0025	0.0044	0.0133	0.0183	0.0382	0.0708	0.0774	0.0148
	Females	0.0151	0.0011	0.0016	0.0023	0.0074	0.0181	0.0268	0.0338	0.0460	0.0599	0.0147
Hispanic	Both Sexes	0.0372	0.0002	0.0014	0.0046	0.0188	0.0452	0.0864	0.1454	0.2137	0.2570	0.0522
	Males	0.0284	-	0.0014	0.0033	0.0102	0.0274	0.0599	0.1279	0.2176	0.3409	0.0470
	Females	0.0462	0.0005	0.0015	0.0059	0.0282	0.0635	0.1128	0.1610	0.2107	0.2049	0.0587

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 17.13
MesotheliomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>								
All Races	Both Sexes	4,144	773	369	299	219	5,804	+	+
	Males	2,918	409	183	121	73	3,706	+	+
	Females	1,226	363	185	178	146	2,098	+	+
White	Both Sexes	3,832	714	344	220	190	5,300	+	+
	Males	2,699	397	178	99	62	3,435	+	+
	Females	1,133	317	166	121	128	1,865	+	+
Black	Both Sexes	163	43	9	53	9	277	+	+
	Males	127	9	0	17	0	154	+	+
	Females	36	34	9	36	9	123	+	+
Asian/ Pacific Islander	Both Sexes	57	14	13	8	3	94	+	+
	Males	37	3	3	4	3	51	+	+
	Females	19	11	10	3	0	43	+	+
Hispanic	Both Sexes	346	71	12	49	5	483	+	+
	Males	230	19	0	37	0	286	+	+
	Females	116	52	12	11	5	197	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0018	-	-	0.0001	0.0004	0.0008	0.0017	0.0039	0.0086	0.0107	0.0015
	Males	0.0023	-	-	0.0001	0.0003	0.0005	0.0017	0.0055	0.0128	0.0210	0.0022
	Females	0.0013	-	-	0.0001	0.0004	0.0011	0.0016	0.0025	0.0051	0.0042	0.0011
White	Both Sexes	0.0021	-	-	0.0001	0.0004	0.0010	0.0018	0.0043	0.0095	0.0112	0.0017
	Males	0.0027	-	-	0.0001	0.0004	0.0006	0.0018	0.0061	0.0140	0.0221	0.0024
	Females	0.0015	-	-	0.0001	0.0004	0.0013	0.0019	0.0026	0.0057	0.0043	0.0012
Black	Both Sexes	0.0006	-	-	-	0.0001	0.0003	0.0006	0.0020	0.0028	0.0085	0.0007
	Males	0.0007	-	-	-	0.0002	-	0.0010	0.0025	0.0033	0.0152	0.0010
	Females	0.0005	-	-	-	-	0.0006	0.0003	0.0016	0.0024	0.0052	0.0005
Asian/ Pacific Islander	Both Sexes	0.0004	-	-	-	0.0004	-	0.0008	0.0010	0.0026	0.0026	0.0005
	Males	0.0005	-	-	-	-	-	0.0011	0.0015	0.0039	0.0044	0.0006
	Females	0.0004	-	-	-	0.0007	-	0.0006	0.0006	0.0015	-	0.0004
Hispanic	Both Sexes	0.0008	-	-	0.0001	0.0002	0.0010	0.0016	0.0029	0.0074	0.0076	0.0013
	Males	0.0010	-	-	-	-	0.0003	0.0016	0.0048	0.0125	0.0171	0.0019
	Females	0.0007	-	-	0.0002	0.0004	0.0016	0.0015	0.0012	0.0034	0.0017	0.0008

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 18.21
Myeloma (Invasive)Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
Race	Sex									
All Races	Both Sexes	83,010	34,877	13,379	5,227	1,922	138,415		2,364	140,779
	Males	46,817	19,011	7,205	2,929	1,026	76,989		912	77,901
	Females	36,193	15,867	6,174	2,297	895	61,426		1,452	62,878
White	Both Sexes	61,910	26,209	10,234	4,118	1,525	103,996		+	+
	Males	36,023	14,655	5,723	2,426	853	59,680		+	+
	Females	25,888	11,554	4,511	1,692	672	44,316		+	+
Black	Both Sexes	17,289	7,185	2,697	838	300	28,309		+	+
	Males	8,728	3,528	1,217	367	146	13,985		+	+
	Females	8,561	3,657	1,481	471	154	14,323		+	+
Asian/ Pacific Islander	Both Sexes	2,444	934	265	145	55	3,843		+	+
	Males	1,322	511	154	60	14	2,062		+	+
	Females	1,122	423	111	85	41	1,782		+	+
Hispanic	Both Sexes	6,755	2,638	969	512	144	11,018		+	+
	Males	3,703	1,452	546	286	95	6,082		+	+
	Females	3,052	1,186	423	226	49	4,936		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races	Both Sexes	0.0427	-	0.0001	0.0003	0.0027	0.0155	0.0476	0.1171	0.2046	0.1997	0.0354
	Males	0.0482	-	0.0001	0.0003	0.0033	0.0177	0.0541	0.1374	0.2544	0.2768	0.0435
	Females	0.0373	-	0.0001	0.0003	0.0021	0.0133	0.0414	0.0987	0.1629	0.1516	0.0289
White	Both Sexes	0.0411	-	0.0001	0.0003	0.0023	0.0131	0.0421	0.1038	0.1857	0.1855	0.0318
	Males	0.0476	-	0.0001	0.0003	0.0028	0.0149	0.0491	0.1240	0.2346	0.2658	0.0399
	Females	0.0347	-	0.0001	0.0003	0.0018	0.0112	0.0353	0.0851	0.1440	0.1345	0.0251
Black	Both Sexes	0.0622	-	0.0001	0.0002	0.0054	0.0339	0.0897	0.2327	0.4028	0.3697	0.0693
	Males	0.0640	-	-	0.0002	0.0064	0.0407	0.0950	0.2651	0.4916	0.4530	0.0814
	Females	0.0605	-	0.0003	0.0002	0.0045	0.0279	0.0851	0.2068	0.3408	0.3281	0.0608
Asian/ Pacific Islander	Both Sexes	0.0184	-	-	0.0003	0.0016	0.0069	0.0232	0.0656	0.1180	0.1174	0.0197
	Males	0.0206	-	-	0.0004	0.0026	0.0077	0.0269	0.0770	0.1487	0.1488	0.0241
	Females	0.0164	-	-	-	0.0007	0.0062	0.0200	0.0565	0.0935	0.0970	0.0162
Hispanic	Both Sexes	0.0190	-	0.0002	0.0004	0.0025	0.0134	0.0408	0.0905	0.1731	0.1463	0.0290
	Males	0.0207	-	0.0002	0.0005	0.0027	0.0159	0.0478	0.1025	0.2122	0.2080	0.0354
	Females	0.0172	-	0.0001	0.0003	0.0024	0.0108	0.0338	0.0797	0.1430	0.1080	0.0240

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 19.25
Non-Hodgkin LymphomaEstimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
Race	Sex									
All Races	Both Sexes	255,823	180,652	122,549	73,159	40,797	672,980		46,851	719,831
	Males	138,660	96,777	62,677	38,089	21,280	357,483		23,952	381,435
	Females	117,164	83,875	59,872	35,070	19,517	315,497		22,899	338,396
White	Both Sexes	219,695	156,580	106,707	64,191	35,524	582,697		45,797	628,494
	Males	119,527	84,275	54,837	33,535	18,538	310,710		24,602	335,312
	Females	100,168	72,306	51,870	30,657	16,986	271,987		21,195	293,182
Black	Both Sexes	21,278	14,055	10,085	5,507	3,114	54,040		3,920	57,960
	Males	11,105	7,321	4,958	2,762	1,599	27,745		1,806	29,551
	Females	10,173	6,734	5,127	2,745	1,516	26,295		2,113	28,409
Asian/ Pacific Islander	Both Sexes	8,776	5,679	3,458	2,114	1,097	21,124		+	+
	Males	4,767	2,942	1,743	1,155	555	11,162		+	+
	Females	4,009	2,737	1,715	959	543	9,962		+	+
Hispanic	Both Sexes	22,714	15,150	8,884	5,187	2,848	54,782		+	+
	Males	11,516	7,891	4,598	2,748	1,541	28,293		+	+
	Females	11,198	7,259	4,286	2,439	1,307	26,489		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races	Both Sexes	0.2076	0.0038	0.0141	0.0284	0.0550	0.1145	0.2415	0.4719	0.8396	1.0538	0.1779
	Males	0.2240	0.0049	0.0188	0.0352	0.0644	0.1325	0.2773	0.5334	0.9656	1.2775	0.2072
	Females	0.1918	0.0026	0.0093	0.0213	0.0456	0.0969	0.2072	0.4162	0.7341	0.9144	0.1532
White	Both Sexes	0.2303	0.0037	0.0145	0.0286	0.0552	0.1170	0.2488	0.4952	0.8825	1.1108	0.1852
	Males	0.2478	0.0051	0.0195	0.0350	0.0651	0.1346	0.2853	0.5554	1.0073	1.3491	0.2149
	Females	0.2131	0.0024	0.0093	0.0217	0.0449	0.0992	0.2132	0.4395	0.7758	0.9597	0.1597
Black	Both Sexes	0.1186	0.0035	0.0117	0.0283	0.0576	0.1067	0.2090	0.3395	0.5280	0.5535	0.1288
	Males	0.1269	0.0039	0.0142	0.0376	0.0651	0.1285	0.2420	0.3946	0.6277	0.5786	0.1493
	Females	0.1110	0.0030	0.0091	0.0189	0.0507	0.0873	0.1803	0.2955	0.4583	0.5410	0.1122
Asian/ Pacific Islander	Both Sexes	0.1013	0.0039	0.0131	0.0214	0.0381	0.0705	0.1448	0.2785	0.4655	0.6095	0.1063
	Males	0.1116	0.0049	0.0171	0.0241	0.0434	0.0772	0.1715	0.3210	0.5661	0.7538	0.1261
	Females	0.0918	0.0028	0.0090	0.0187	0.0333	0.0645	0.1217	0.2442	0.3850	0.5155	0.0905
Hispanic	Both Sexes	0.0942	0.0028	0.0124	0.0209	0.0411	0.0861	0.1906	0.3754	0.6108	0.7555	0.1347
	Males	0.0963	0.0034	0.0149	0.0256	0.0477	0.0967	0.2065	0.4086	0.6404	0.8419	0.1475
	Females	0.0921	0.0022	0.0097	0.0158	0.0338	0.0753	0.1749	0.3460	0.5880	0.7018	0.1237

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 20.27
Cancer of the Oral Cavity and Pharynx (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
Race	Sex									
All Races	Both Sexes	142,423	86,829	54,304	34,031	21,157	338,744		44,671	383,415
	Males	100,634	59,611	36,476	22,012	12,660	231,393		28,184	259,578
	Females	41,789	27,218	17,828	12,019	8,497	107,350		16,487	123,837
White	Both Sexes	123,336	75,584	47,130	29,262	18,188	293,500		37,477	330,977
	Males	88,047	52,661	32,186	19,319	11,021	203,234		23,696	226,930
	Females	35,290	22,923	14,945	9,943	7,167	90,266		13,781	104,048
Black	Both Sexes	10,449	6,031	3,684	2,563	1,566	24,293		2,221	26,514
	Males	7,180	3,746	2,172	1,407	827	15,332		1,165	16,497
	Females	3,270	2,285	1,512	1,155	739	8,961		1,055	10,017
Asian/ Pacific Islander	Both Sexes	5,720	3,471	2,366	1,510	894	13,961		+	+
	Males	3,474	2,117	1,394	861	512	8,357		+	+
	Females	2,246	1,355	973	649	382	5,604		+	+
Hispanic	Both Sexes	8,309	4,940	2,868	1,786	1,126	19,029		+	+
	Males	5,476	2,992	1,745	1,070	534	11,817		+	+
	Females	2,833	1,948	1,123	715	592	7,212		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		All Ages	0-9	10-19	20-29	Age Specific (Crude)					Age-Adjusted ^c	
Race	Sex											
All Races	Both Sexes	0.1045	0.0003	0.0025	0.0067	0.0169	0.0501	0.1537	0.3084	0.3952	0.3656	0.0859
	Males	0.1450	0.0004	0.0023	0.0063	0.0166	0.0615	0.2236	0.4756	0.6049	0.5471	0.1255
	Females	0.0653	0.0003	0.0027	0.0071	0.0171	0.0389	0.0868	0.1571	0.2197	0.2525	0.0522
White	Both Sexes	0.1160	0.0004	0.0024	0.0062	0.0163	0.0495	0.1599	0.3250	0.4171	0.3861	0.0895
	Males	0.1621	0.0004	0.0021	0.0056	0.0159	0.0612	0.2347	0.5020	0.6360	0.5754	0.1310
	Females	0.0707	0.0003	0.0026	0.0069	0.0167	0.0378	0.0868	0.1611	0.2299	0.2661	0.0532
Black	Both Sexes	0.0533	0.0003	0.0028	0.0080	0.0142	0.0383	0.1065	0.2014	0.2353	0.1727	0.0553
	Males	0.0701	0.0005	0.0026	0.0090	0.0142	0.0443	0.1487	0.3041	0.3754	0.2772	0.0800
	Females	0.0378	-	0.0029	0.0070	0.0142	0.0330	0.0698	0.1193	0.1373	0.1205	0.0370
Asian/ Pacific Islander	Both Sexes	0.0669	-	0.0023	0.0064	0.0235	0.0632	0.1335	0.2133	0.2487	0.2397	0.0675
	Males	0.0836	-	0.0024	0.0071	0.0254	0.0775	0.1768	0.3021	0.3448	0.3145	0.0895
	Females	0.0516	-	0.0022	0.0058	0.0217	0.0506	0.0960	0.1417	0.1717	0.1910	0.0496
Hispanic	Both Sexes	0.0327	0.0005	0.0020	0.0047	0.0104	0.0287	0.0735	0.1541	0.2109	0.2352	0.0469
	Males	0.0402	0.0007	0.0020	0.0044	0.0096	0.0326	0.0997	0.2200	0.2972	0.3345	0.0636
	Females	0.0251	0.0003	0.0020	0.0050	0.0112	0.0247	0.0475	0.0955	0.1443	0.1737	0.0332

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 21.15
Cancer of the Ovary (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>								
All Races	71,556	41,438	30,133	23,852	18,922	185,902	47,462	233,364
White	60,669	35,835	26,117	20,920	16,566	160,107	40,165	200,272
Black	6,119	2,753	2,000	1,492	1,374	13,737	4,436	18,173
Asian/Pacific Islander	3,666	2,200	1,615	1,120	730	9,332	+	+
Hispanic	8,044	4,505	2,839	1,805	1,424	18,617	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^c
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races	0.1130	0.0004	0.0058	0.0198	0.0399	0.0829	0.1779	0.2851	0.3429	0.2841	0.0920
White	0.1254	0.0004	0.0058	0.0208	0.0417	0.0861	0.1872	0.3055	0.3654	0.2987	0.0971
Black	0.0580	0.0003	0.0048	0.0149	0.0327	0.0602	0.1081	0.1596	0.1872	0.1772	0.0573
Asian/Pacific Islander	0.0860	0.0008	0.0055	0.0175	0.0363	0.0872	0.1882	0.2361	0.2520	0.1910	0.0813
Hispanic	0.0647	0.0005	0.0066	0.0251	0.0426	0.0761	0.1476	0.2425	0.2529	0.2448	0.0798

^a Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years.

Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 22.21
Cancer of the Pancreas (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
Race	Sex									
All Races	Both Sexes	57,729	10,952	4,618	1,929	1,010	76,239		2,731	78,969
	Males	29,053	5,759	1,879	922	286	37,899		1,296	39,194
	Females	28,677	5,193	2,739	1,007	724	38,340		1,435	39,775
White	Both Sexes	47,797	8,888	3,811	1,535	804	62,836		2,220	65,055
	Males	24,315	4,813	1,594	812	246	31,779		1,120	32,898
	Females	23,482	4,075	2,218	724	558	31,057		1,100	32,157
Black	Both Sexes	6,894	1,388	510	247	114	9,153		861	10,015
	Males	3,194	619	177	70	9	4,069		404	4,473
	Females	3,700	770	333	177	105	5,085		457	5,541
Asian/ Pacific Islander	Both Sexes	2,378	526	211	85	52	3,252		+	+
	Males	1,159	241	85	20	13	1,518		+	+
	Females	1,219	285	127	64	38	1,734		+	+
Hispanic	Both Sexes	4,702	805	408	181	108	6,204		+	+
	Males	2,021	361	133	71	5	2,591		+	+
	Females	2,681	445	274	110	103	3,613		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
Race	Sex											
All Races	Both Sexes	0.0235	0.0000	0.0004	0.0011	0.0033	0.0103	0.0283	0.0650	0.1048	0.0977	0.0196
	Males	0.0237	0.0001	0.0003	0.0004	0.0026	0.0087	0.0291	0.0723	0.1202	0.1108	0.0211
	Females	0.0233	-	0.0005	0.0018	0.0040	0.0118	0.0275	0.0585	0.0919	0.0896	0.0184
White	Both Sexes	0.0248	0.0000	0.0004	0.0012	0.0031	0.0097	0.0272	0.0643	0.1057	0.0980	0.0194
	Males	0.0253	0.0001	0.0003	0.0004	0.0026	0.0082	0.0281	0.0722	0.1202	0.1132	0.0210
	Females	0.0243	-	0.0004	0.0021	0.0037	0.0112	0.0263	0.0569	0.0933	0.0884	0.0181
Black	Both Sexes	0.0201	-	0.0003	0.0006	0.0039	0.0130	0.0366	0.0770	0.1050	0.0895	0.0216
	Males	0.0186	-	0.0003	0.0005	0.0027	0.0098	0.0382	0.0814	0.1264	0.0690	0.0219
	Females	0.0215	-	0.0003	0.0007	0.0050	0.0159	0.0352	0.0735	0.0900	0.0997	0.0213
Asian/ Pacific Islander	Both Sexes	0.0156	0.0003	0.0009	0.0007	0.0039	0.0101	0.0224	0.0497	0.0814	0.0921	0.0164
	Males	0.0152	0.0005	0.0005	0.0004	0.0028	0.0112	0.0218	0.0488	0.0987	0.1006	0.0176
	Females	0.0160	-	0.0014	0.0010	0.0048	0.0091	0.0230	0.0505	0.0675	0.0865	0.0156
Hispanic	Both Sexes	0.0107	-	0.0004	0.0014	0.0030	0.0086	0.0211	0.0516	0.0801	0.0840	0.0158
	Males	0.0088	-	0.0005	0.0004	0.0014	0.0065	0.0181	0.0490	0.0875	0.0799	0.0149
	Females	0.0126	-	0.0004	0.0025	0.0047	0.0108	0.0241	0.0540	0.0744	0.0866	0.0167

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 23.15
Cancer of the Prostate (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>								
All Races	900,214	953,463	678,436	418,862	184,721	3,135,696	34,643	3,170,339
White	701,239	769,223	563,050	354,061	159,744	2,547,317	36,576	2,583,893
Black	138,010	131,943	86,907	50,644	20,399	427,902	4,086	431,988
Asian/Pacific Islander	21,319	20,629	13,351	6,827	2,333	64,458	+	+
Hispanic	59,273	57,004	38,768	20,529	7,678	183,252	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^c
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races	1.9646	0.0001	0.0002	0.0003	0.0007	0.0628	0.9938	4.9473	12.7506	17.7721	1.8324
White	2.0311	0.0002	0.0003	0.0003	0.0005	0.0480	0.8646	4.5811	12.2431	17.3251	1.7432
Black	1.9574	-	-	0.0002	0.0017	0.1674	1.9500	8.2063	18.4635	22.7226	2.7051
Asian/Pacific Islander	0.6447	-	-	-	-	0.0144	0.2968	1.9438	5.7590	9.4841	0.8397
Hispanic	0.6240	0.0002	0.0002	0.0001	0.0005	0.0286	0.5448	3.1347	9.2044	13.7068	1.3137

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 24.21
Cancer of the Stomach (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	54,042	26,380	15,002	8,205	4,582	108,211		8,314	116,525
	Males	31,365	14,818	8,175	4,623	2,463	61,445		4,737	66,182
	Females	22,676	11,561	6,828	3,581	2,119	46,766		3,577	50,343
White	Both Sexes	40,902	19,944	11,203	6,216	3,412	81,678		6,451	88,128
	Males	24,172	11,626	6,356	3,582	1,764	47,500		3,650	51,150
	Females	16,730	8,319	4,846	2,634	1,649	34,178		2,800	36,978
Black	Both Sexes	7,637	3,672	2,018	1,066	551	14,944		1,053	15,997
	Males	4,025	1,697	872	528	315	7,437		559	7,995
	Females	3,612	1,975	1,146	538	236	7,508		494	8,002
Asian/ Pacific Islander	Both Sexes	4,275	2,224	1,475	795	490	9,260		+	+
	Males	2,513	1,182	811	430	292	5,229		+	+
	Females	1,762	1,041	664	366	197	4,031		+	+
Hispanic	Both Sexes	7,803	3,705	2,132	1,059	616	15,315		+	+
	Males	4,041	1,942	1,110	565	265	7,924		+	+
	Females	3,762	1,762	1,022	494	351	7,391		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.0334	-	0.0001	0.0008	0.0042	0.0130	0.0364	0.0775	0.1495	0.2060	0.0281
	Males	0.0385	-	0.0001	0.0007	0.0040	0.0130	0.0407	0.0970	0.1986	0.2835	0.0356
	Females	0.0284	-	0.0002	0.0009	0.0043	0.0130	0.0323	0.0598	0.1084	0.1577	0.0223
White	Both Sexes	0.0323	-	0.0002	0.0008	0.0040	0.0124	0.0325	0.0692	0.1356	0.1847	0.0254
	Males	0.0379	-	0.0001	0.0007	0.0037	0.0127	0.0367	0.0875	0.1823	0.2577	0.0325
	Females	0.0268	-	0.0002	0.0009	0.0042	0.0120	0.0283	0.0523	0.0957	0.1384	0.0197
Black	Both Sexes	0.0328	-	-	0.0007	0.0042	0.0130	0.0506	0.1105	0.2003	0.2648	0.0372
	Males	0.0340	-	-	0.0007	0.0045	0.0115	0.0537	0.1303	0.2612	0.3351	0.0450
	Females	0.0317	-	-	0.0007	0.0038	0.0143	0.0480	0.0946	0.1578	0.2297	0.0321
Asian/ Pacific Islander	Both Sexes	0.0444	-	0.0003	0.0010	0.0044	0.0174	0.0507	0.1206	0.2650	0.4661	0.0493
	Males	0.0523	-	-	0.0011	0.0046	0.0169	0.0616	0.1660	0.3448	0.6321	0.0641
	Females	0.0371	-	0.0005	0.0009	0.0043	0.0179	0.0413	0.0840	0.2011	0.3579	0.0381
Hispanic	Both Sexes	0.0263	-	0.0001	0.0008	0.0059	0.0189	0.0498	0.1070	0.2280	0.3134	0.0415
	Males	0.0270	-	0.0001	0.0007	0.0056	0.0187	0.0516	0.1207	0.2862	0.3924	0.0489
	Females	0.0257	-	0.0001	0.0010	0.0063	0.0192	0.0480	0.0948	0.1832	0.2643	0.0360

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 25.15
Cancer of the Testis (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity and Years Since Diagnosis

Years Since Diagnosis	0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b	> 25 ^d	Complete ^e
<u>Race</u>								
All Races	45,178	41,456	38,203	35,875	31,655	192,368	77,402	269,769
White	40,808	38,024	35,895	33,706	30,097	178,530	72,670	251,200
Black	1,478	1,287	969	999	711	5,444	1,829	7,274
Asian/Pacific Islander	1,273	913	657	626	494	3,962	+	+
Hispanic	8,235	6,787	5,021	3,778	2,623	26,445	+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^c	
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages	
<u>Race</u>												
All Races	0.1205	0.0023	0.0072	0.0758	0.2020	0.2563	0.2324	0.1278	0.0530	0.0240	0.1209	
White	0.1424	0.0022	0.0082	0.0923	0.2411	0.3030	0.2684	0.1436	0.0587	0.0260	0.1421	
Black	0.0249	0.0024	0.0031	0.0104	0.0405	0.0558	0.0551	0.0360	0.0112	0.0079	0.0265	
Asian/Pacific Islander	0.0396	0.0034	0.0042	0.0322	0.0658	0.0715	0.0683	0.0437	0.0129	0.0071	0.0382	
Hispanic	0.0900	0.0026	0.0114	0.0934	0.1911	0.1841	0.1357	0.0638	0.0342	0.0093	0.0938	

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 26.21
Cancer of the Thyroid (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	231,706	190,426	126,803	80,597	56,569	686,101	173,737	859,838	
	Males	56,375	41,757	26,946	16,660	11,811	153,550	40,548	194,098	
	Females	175,330	148,669	99,857	63,937	44,758	532,551	133,189	665,740	
White	Both Sexes	195,432	163,435	111,041	71,352	50,080	591,341	153,707	745,047	
	Males	49,044	36,941	24,228	15,099	10,702	136,015	34,423	170,438	
	Females	146,388	126,494	86,813	56,253	39,378	455,326	119,283	574,609	
Black	Both Sexes	17,046	13,329	7,854	4,211	2,890	45,330	9,545	54,875	
	Males	3,157	2,180	1,295	669	503	7,803	1,444	9,247	
	Females	13,889	11,150	6,559	3,542	2,388	37,527	8,100	45,628	
Asian/ Pacific Islander	Both Sexes	13,318	9,772	5,992	3,817	2,600	35,499	+	+	
	Males	2,903	1,828	988	689	405	6,813	+	+	
	Females	10,415	7,944	5,004	3,128	2,195	28,686	+	+	
Hispanic	Both Sexes	29,121	20,368	12,721	7,789	5,169	75,168	+	+	
	Males	5,359	3,352	2,028	1,235	825	12,800	+	+	
	Females	23,762	17,015	10,693	6,554	4,343	62,368	+	+	

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.2117	0.0002	0.0068	0.0510	0.1608	0.3079	0.4016	0.4364	0.4433	0.3201	0.1925
	Males	0.0962	0.0002	0.0032	0.0173	0.0517	0.1160	0.1714	0.2330	0.2817	0.2263	0.0884
	Females	0.3237	0.0002	0.0106	0.0863	0.2709	0.4967	0.6217	0.6205	0.5784	0.3785	0.2913
White	Both Sexes	0.2337	0.0003	0.0078	0.0581	0.1803	0.3341	0.4327	0.4565	0.4564	0.3291	0.2066
	Males	0.1085	0.0002	0.0035	0.0201	0.0577	0.1274	0.1864	0.2477	0.2957	0.2366	0.0953
	Females	0.3567	0.0003	0.0123	0.0982	0.3072	0.5432	0.6734	0.6500	0.5939	0.3878	0.3149
Black	Both Sexes	0.0995	-	0.0020	0.0163	0.0618	0.1627	0.2122	0.2701	0.3140	0.2105	0.1055
	Males	0.0357	-	0.0013	0.0033	0.0160	0.0473	0.0795	0.1218	0.1543	0.1231	0.0412
	Females	0.1584	-	0.0027	0.0294	0.1041	0.2650	0.3278	0.3886	0.4256	0.2542	0.1590
Asian/ Pacific Islander	Both Sexes	0.1702	-	0.0064	0.0423	0.1273	0.2634	0.3390	0.4113	0.3969	0.3042	0.1679
	Males	0.0681	-	0.0034	0.0129	0.0436	0.0999	0.1366	0.1852	0.2197	0.1682	0.0717
	Females	0.2642	-	0.0094	0.0718	0.2035	0.4080	0.5144	0.5934	0.5387	0.3930	0.2501
Hispanic	Both Sexes	0.1293	0.0001	0.0073	0.0429	0.1285	0.2358	0.3209	0.3835	0.3990	0.2964	0.1598
	Males	0.0436	-	0.0034	0.0112	0.0332	0.0738	0.1055	0.1619	0.1988	0.1727	0.0596
	Females	0.2168	0.0002	0.0112	0.0774	0.2322	0.4025	0.5342	0.5803	0.5533	0.3731	0.2561

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.

Table 27.21
Cancer of the Urinary Bladder (Invasive and *In Situ*)

Estimated United States Cancer Prevalence Counts^a on January 1, 2017
By Race/Ethnicity, Sex and Years Since Diagnosis

Years Since Diagnosis		0 to 5	> 5 to 10	> 10 to 15	> 15 to 20	> 20 to 25	<=25 ^b		> 25 ^d	Complete ^e
<u>Race</u>	<u>Sex</u>									
All Races	Both Sexes	259,043	167,498	111,316	69,467	42,775	650,100		62,514	712,614
	Males	199,779	127,337	82,853	50,783	31,234	491,986		43,954	535,940
	Females	59,264	40,161	28,464	18,683	11,542	158,113		18,560	176,673
White	Both Sexes	233,946	152,724	102,120	64,825	39,928	593,542		48,882	642,424
	Males	181,402	116,507	76,192	47,608	29,099	450,808		34,255	485,063
	Females	52,544	36,217	25,928	17,217	10,829	142,734		14,627	157,361
Black	Both Sexes	14,511	8,367	5,150	2,792	1,726	32,546		1,752	34,299
	Males	10,380	6,056	3,581	1,786	1,290	23,093		1,395	24,488
	Females	4,131	2,311	1,569	1,006	436	9,453		357	9,810
Asian/ Pacific Islander	Both Sexes	5,612	3,381	2,170	1,095	601	12,859		+	+
	Males	4,257	2,554	1,666	772	452	9,702		+	+
	Females	1,355	826	504	323	149	3,157		+	+
Hispanic	Both Sexes	11,699	6,971	4,257	2,492	1,519	26,938		+	+
	Males	8,922	5,118	3,242	1,832	1,085	20,199		+	+
	Females	2,777	1,853	1,014	660	434	6,739		+	+

Estimated prevalence percent^a on January 1, 2017, of the SEER population diagnosed in the previous 25 years
By Age at Prevalence, Race/Ethnicity and Sex

Age at Prevalence		Age Specific (Crude)										Age-Adjusted ^c
		All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>	<u>Sex</u>											
All Races	Both Sexes	0.2006	0.0003	0.0004	0.0019	0.0077	0.0278	0.1160	0.4028	1.0515	1.7621	0.1688
	Males	0.3082	0.0004	0.0005	0.0026	0.0107	0.0418	0.1780	0.6544	1.7773	3.3834	0.2948
	Females	0.0961	0.0002	0.0003	0.0011	0.0047	0.0141	0.0567	0.1750	0.4443	0.7525	0.0732
White	Both Sexes	0.2346	0.0002	0.0004	0.0020	0.0088	0.0311	0.1263	0.4354	1.1387	1.8823	0.1820
	Males	0.3595	0.0003	0.0005	0.0030	0.0121	0.0457	0.1923	0.6993	1.9092	3.5960	0.3151
	Females	0.1118	0.0002	0.0003	0.0011	0.0054	0.0163	0.0618	0.1908	0.4799	0.7959	0.0788
Black	Both Sexes	0.0715	0.0007	0.0004	0.0010	0.0036	0.0150	0.0667	0.2260	0.5030	0.8498	0.0854
	Males	0.1056	0.0011	0.0003	0.0005	0.0049	0.0257	0.1017	0.3879	0.8788	1.6336	0.1528
	Females	0.0399	0.0003	0.0005	0.0016	0.0024	0.0056	0.0363	0.0967	0.2402	0.4584	0.0421
Asian/ Pacific Islander	Both Sexes	0.0617	0.0003	-	0.0007	0.0029	0.0106	0.0498	0.1630	0.3956	0.8129	0.0702
	Males	0.0970	0.0005	-	0.0008	0.0042	0.0166	0.0816	0.2835	0.6798	1.5086	0.1244
	Females	0.0291	-	-	0.0006	0.0018	0.0052	0.0223	0.0658	0.1681	0.3593	0.0301
Hispanic	Both Sexes	0.0463	0.0003	0.0003	0.0013	0.0050	0.0133	0.0545	0.1756	0.4932	0.8497	0.0799
	Males	0.0688	0.0006	0.0005	0.0018	0.0065	0.0189	0.0809	0.2821	0.8663	1.6480	0.1417
	Females	0.0234	0.0001	0.0002	0.0007	0.0034	0.0075	0.0284	0.0810	0.2057	0.3541	0.0349

^a US 2017 cancer prevalence counts are based on 2017 cancer prevalence proportions from the SEER 13 Areas (excluding the Alaska Native Registry) and 1/1/2017 US population estimates based on the average of 2016 and 2017 population estimates from the US Bureau of the Census.

^b Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 25 years. Maximum limited-duration prevalence is 25 years for 1992-2017 data.

^c Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups.

^d Cases diagnosed more than 25 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

^e Complete prevalence is obtained by summing <=25 and > 25.

- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.

+ Not available.